Prostate cancer drug given initial 'no' for NHS in England

June 8, 2018, Cancer Research UK
Prostate cancer drug given initial ‘no’ for NHS in England
Credit: Cancer Research UK

A prostate cancer drug has been provisionally rejected as a first-line treatment on the NHS in England.

The draft recommendation from the National Institute for Health and Care Excellence (NICE) means abiraterone (Zytiga) won't be made routinely available for men with newly diagnosed that has spread to other parts of the body.

As it stands, the NHS in England can only prescribe abiraterone for these men once standard hormone treatment or chemotherapy has failed.

Results from recent clinical trials have shown that giving abiraterone alongside steroids and as a first-line treatment can reduce the chance of the cancer coming back and improve survival compared to hormone therapy alone.

Sir Harpal Kumar, Cancer Research UK's chief executive, called the decision "disappointing". "Two published last year provided compelling evidence of the huge potential benefit of abiraterone for these patients," he said.

What does the decision mean?

NICE published its draft recommendation this week, rejecting abiraterone as a first-line therapy. The committee concluded they couldn't accurately estimate the drug's cost effectiveness based on the data submitted.

The drug's manufacturer, Janssen, can now submit additional data, which will be reviewed later this summer before a final decision is reached.

A NICE spokesperson told The Telegraph : "We understand that some men with prostate will be disappointed by today's news.

"However, we can only recommend drugs that are clinically effective and show value for money compared to current treatment options. In this case, has fallen short."

Kumar urged NICE and Janssen to work together quickly to provide the information that will allow the drug to be recommended.

Explore further: Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent

Related Stories

Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent

June 3, 2017
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the ...

Trial shows responses to abiraterone acetate in some prostate cancer patients with initial hormone induction failure

April 5, 2017
Patients with metastatic prostate cancer whose PSA levels remain high despite initial hormone treatments have historically had poor prognosis, with survival typically in the 1-2 year range. Results of a 40-person clinical ...

Treatment extends life for some with advanced prostate cancer

June 3, 2017
Adding a new anti-hormonal drug to the standard treatment for advanced prostate cancer has been shown to reduce the risk of dying by almost 40 percent, according to two studies published Saturday.

Tests identify who would benefit from advanced prostate cancer therapies

June 5, 2018
Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors and patient added clarity on treatment options, according to a study led ...

Prostate drug decision highlights urgent need for reform

August 18, 2014
Just a week after the controversy over breast cancer drug Kadcyla, the inflexibilities within the UK's disparate drug approval systems have been pulled into sharp focus once again.

Abiraterone delays metastatic prostate cancer growth by 18 months, extends survival

June 5, 2017
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 ...

Recommended for you

First immunotherapy success for triple-negative breast cancer

October 21, 2018
There is new hope for people with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer.

Healthy diets linked to better outcomes in colorectal cancer

October 20, 2018
Colorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved their diets after being diagnosed, according to a new American Cancer Society ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.